Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study

Recombinant factor IX Fc fusion protein (rFIXFc) has demonstrated efficacy for treatment of haemophilia B in the Phase 3 B‐LONG and Kids B‐LONG studies. However, long‐term rFIXFc safety and efficacy data have not yet been reported.

[1]  J. Mahlangu.  Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B , 2018, Therapeutic advances in hematology.

[2]  C. Hermans,et al.  Practical aspects of extended half-life products for the treatment of haemophilia , 2018, Therapeutic advances in hematology.

[3]  G. Castaman.  The benefits of prophylaxis in patients with hemophilia B , 2018, Expert review of hematology.

[4]  C. Santoro,et al.  Inhibitors in Hemophilia B , 2018, Seminars in Thrombosis and Hemostasis.

[5]  R. Peters,et al.  Advances and innovations in haemophilia treatment , 2018, Nature Reviews Drug Discovery.

[6]  C. Wang,et al.  Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  G. Young,et al.  Clinical Use of Recombinant Factor VIII Fc and Recombinant Factor IX Fc in Patients with Hemophilia A and B , 2017 .

[8]  J. Oldenburg,et al.  Haemophilia patients’ unmet needs and their expectations of the new extended half‐life factor concentrates , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  K. Fischer,et al.  Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. , 2017, The Lancet. Haematology.

[10]  J. Oldenburg,et al.  Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. , 2016, Thrombosis and haemostasis.

[11]  T. Lambert,et al.  Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children , 2016, Thrombosis and Haemostasis.

[12]  J. Oldenburg,et al.  Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A , 2016, Thrombosis and Haemostasis.

[13]  J. Oldenburg,et al.  Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). , 2016, Thrombosis research.

[14]  A. Iorio,et al.  Inhibitor development in haemophilia according to concentrate , 2015, Thrombosis and Haemostasis.

[15]  J. Oldenburg,et al.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. , 2014, Blood.

[16]  V. Jiménez‐Yuste,et al.  Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. , 2014, Blood transfusion = Trasfusione del sangue.

[17]  I. Nestorov,et al.  Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B , 2014, Clinical Pharmacokinetics.

[18]  J. Dumont,et al.  Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. , 2013, The New England journal of medicine.

[19]  K. A. Stafford,et al.  Evidence of clinically significant extravascular stores of factor IX , 2013, Journal of thrombosis and haemostasis : JTH.

[20]  A. Shapiro.  Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia , 2013, Expert opinion on biological therapy.

[21]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  M. Morfini,et al.  Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. , 2012, Blood.

[23]  A. Bitonti,et al.  Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. , 2012, Blood.

[24]  M. Strandberg-Larsen,et al.  Haemophilia B: impact on patients and economic burden of disease , 2011, Thrombosis and Haemostasis.

[25]  L. Mantovani,et al.  A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.

[26]  A. Bitonti,et al.  Prolonged activity of factor IX as a monomeric Fc fusion protein. , 2010, Blood.

[27]  P. Monahan,et al.  Abnormal hemostasis in a knock‐in mouse carrying a variant of factor IX with impaired binding to collagen type IV , 2009, Journal of thrombosis and haemostasis : JTH.

[28]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[29]  J. Ahnström,et al.  A 6‐year follow‐up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.